[Glial volume test for patients with schizophrenia and its changes during therapy]

Glial volume test (GVT) was used to assess cytotoxic antibrain antibodies in 64 schizophrenic patients and 42 patients with organic disorders of the central nervous system. The GVT changes were unspecific and reflected the general course of the disease. Serum cytotoxicity increased with increasing psychopathological signs and reduced to normal or subnormal values with their alleviation. The results of the treatment were dependent on the baseline GVT levels. The test can be used as an objective prognostic criterion for the course of the disease and treatment efficiency.